Focus Partners Wealth
IOVA icon

Focus Partners Wealth’s Iovance Biotherapeutics IOVA Stock Holding History

Focus Partners Wealth’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117K Buy
+28,006
New +$106K ﹤0.01% 2601

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Focus Partners Wealth's IOVA Position: Q2 2026 in Review

Focus Partners Wealth opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 28,006 shares worth $117K. The stake represents ﹤0.01% of the portfolio and ranks #2601 among its holdings.

292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Focus Partners Wealth held 28,006 shares of Iovance Biotherapeutics worth $117K as of Q2 2026.
  • Iovance Biotherapeutics was a new Focus Partners Wealth position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2601 holding.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.